

14 June 2016

## **Operational Update**

### New Clinical Trial

The Board of Resonance Health (ASX: RHT) today announced a new two year collaboration for the provision of FerriScan and Cardiac T2\* analysis services for an Asia-based component of a pharmaceutical company Phase 3 clinical trial. Service provision for the trial is expected to commence shortly.

FerriScan is recognised globally as the gold standard for the measurement of liver iron concentration due to its non-invasive nature, accuracy, and standardised results. It is widely used in over 30 countries globally by both clinicians managing patients with iron overload disorders and pharmaceutical company clinical trials, alike.

Resonance Health's General Manager, Sander Bangma, commented:

*"In order to assess the efficacy of their investigational products, pharmaceutical companies require consistently accurate, quantitative measurements. It is a testament to Resonance Health that our ISO-certified analysis services are commonly chosen for this purpose.*

*Resonance Health's expertise in the provision of imaging core lab services for pharmaceutical clinical trials has been utilised in over 20 international multicenter studies over the past 10 years. We are proud to have such endorsement by pharmaceutical companies and are delighted to be able to further contribute to improved patient outcomes as a result."*

### Launch of Corporate FerriScan Video

Resonance Health recently exhibited at the European Hematology Association (EHA) 21st Congress in Copenhagen, Denmark. EHA is Europe's premier hematology congress and provided the opportunity to meet with pharmaceutical companies and key opinion leaders. Resonance Health was excited to use the opportunity to launch its Corporate FerriScan video at this event. The video has already proven itself as a powerful tool to succinctly educate on benefits of FerriScan and has been well-received by the delegates attending the conference.

The short video is an asset at busy congress booths, on the Company website, and for the wider public as a tool to deliver the key advantages of FerriScan to clinicians, pharmaceutical companies, patients, and other stakeholders. Please [click here](#) to view the video.

#### Service Provision

The Company is also pleased to report that its Service Centre is currently analysing record volumes of scans. The increased demand is being driven by both marketing activities, resulting in increased routine clinical use of our services, as well as the roll out of various collaborative studies with patient recruitment now being well established.

#### **For further information contact:**

Sander Bangma

General Manager, Resonance Health

E: [SanderB@resonancehealth.com](mailto:SanderB@resonancehealth.com) P: +61 (0)8 92845300